title: The renin-angiotensin system and its vasoactive metabolite angiotensin-(1-7) in the mechanism of the healing of preexisting gastric ulcers. The involvement of Mas receptors, nitric oxide, prostaglandins and proinflammatory cytokines.
abstract: The inhibition of angiotensin-converting enzyme (ACE) or the blockade of angiotensin (Ang) AT-1 receptors affords protection against acute gastric mucosal injury, but whether the major metabolite of renin-angiotensin system (RAS), Ang-(1-7), accelerates the healing process of preexisting gastric ulcers remains unknown. Previous studies documented that Ang-(1-7) acting via its own Mas receptor exerts vascular responses opposing those of Ang II. We studied the effects of the Ang-(1-7)/Mas receptor axis on the healing rate of acetic-acid-induced gastric ulcers with or without the blockade of Mas receptors by A 779 and compared it with the effects of activation and blockade of the AT-1 receptor by the treatment with Ang II and losartan, respectively, the inhibition of ACE by lisinopril, the NO/cNOS inhibition by L-NAME and inhibition of prostaglandin/COX system by indomethacin in the presence of Ang-(1-7). Additionally, ex vivo metabolism of Ang I in gastric tissue was assessed by LC/MS method. At day 9 after ulcer induction, the area of these ulcers and the accompanying changes in total gastric blood flow (GBF) were determined as were gastric mucosal blood flow (GMBF) at ulcer margin and gastric oxygen uptake (GVO2). The gastric mucosal expression of mRNAs for constitutive nitric oxide synthase (cNOS), superoxide dismutase (SOD), and pro-inflammatory cytokines interleukin 1β (IL-1β) and tumor necrosis factor alpha (TNF-α) and plasma level of both cytokines were determined by RT-PCR and ELISA. The 9 days treatment with Ang II dose-dependently increased the area of gastric ulcers and this effect was accompanied by a significant fall in the GBF, GVO2 and GMBF at ulcer margin. In contrast, treatment with Ang-(1-7) which produced a significant rise in the luminal content of NO significantly reduced the area of gastric ulcer and significantly increased the GBF, GVO2 and the GMBF at ulcer margin. Similar GMBF changes and significant reduction the area of gastric ulcer was observed in rats with gastric ulcers treated with the agonist of Mas receptor, AVE 0991. These effects of Ang-(1-7) and AVE 0991 were eliminated by blockade of the Mas receptor with A779. Similarly to Ang-(1-7), treatment with losartan or lisinopril significantly reduced the area of gastric ulcers and the accompanying increase in the GMBF at ulcer margin and these effects were significantly attenuated by a concomitant administration of L-NAME and indomethacin. The rate of healing of ulcers was associated with a decrease in ex vivo Ang-(1-7) formation and this effect was attenuated by lisinopril. The treatment with Ang-(1- 7) or AVE 0991 increased the expression of mRNA for cNOS and SOD and downregulated that of IL-1β and TNF-α followed by the decrease in the plasma IL-1β and TNF-α levels. We conclude that the Ang-(1-7)/Mas receptor system accelerates the healing of preexisting gastric ulcers via an increase in the gastric macro- and microcirculations, and an increase in gastric tissue oxygenation. These effects are mediated by PG and NO derived from overexpression of cNOS, an increase in the expression of antioxidizing enzyme SOD 2 and an anti-inflammatory action involving the inhibition of expression and release of pro-inflammatory cytokines IL-1β and TNF-α. Our results seem to underlie the importance of the Ang-(1-7), AT-1 and Mas receptors in the regulation of local vascular and metabolic effects associated with mechanism of gastric ulcer healing.
authors.affiliation: Department of Physiology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: M W
authors.initials: MW
authors.lastname: Pawlik
authors.affiliation: Department of Physiology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: S
authors.initials: S
authors.lastname: Kwiecien
authors.affiliation: Department of Physiology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Ptak-Belowska
authors.affiliation: Department of Physiology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: R
authors.initials: R
authors.lastname: Pajdo
authors.affiliation: Department of Pharmacology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: R
authors.initials: R
authors.lastname: Olszanecki
authors.affiliation: Department of Pharmacology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Suski
authors.affiliation: Department of Pharmacology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Madej
authors.affiliation: Department of Physiology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Targosz
authors.affiliation: Department of Physiology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: S J
authors.initials: SJ
authors.lastname: Konturek
authors.affiliation: Department of Pharmacology Jagiellonian University Medical College, Cracow, Poland.
authors.forename: R
authors.initials: R
authors.lastname: Korbut
authors.affiliation: Department of Pharmacology Jagiellonian University Medical College, Cracow, Poland. mpbrzozo@cyf- kr.edu.pl.
authors.forename: T
authors.initials: T
authors.lastname: Brzozowski
mesh_terms: D000803:Angiotensin I / Q000378:metabolism*; D000804:Angiotensin II / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D016207:Cytokines / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D007093:Imidazoles / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D053583:Interleukin-1beta / Q000378:metabolism; D017706:Lisinopril / Q000494:pharmacology; D019808:Losartan / Q000494:pharmacology; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism*; D011453:Prostaglandins / Q000378:metabolism*; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013276:Stomach Ulcer / Q000378:metabolism*; D013482:Superoxide Dismutase / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: C469726:AVE 0991; D000806:Angiotensin-Converting Enzyme Inhibitors; D016207:Cytokines; D004791:Enzyme Inhibitors; D007093:Imidazoles; D053583:Interleukin-1beta; D010446:Peptide Fragments; D011453:Prostaglandins; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D043562:Receptors, G-Protein-Coupled; D014409:Tumor Necrosis Factor-alpha; D000804:Angiotensin II; D009569:Nitric Oxide; D000803:Angiotensin I; D017706:Lisinopril; D019001:Nitric Oxide Synthase; D013482:Superoxide Dismutase; C118790:angiotensin I (1-7); D019808:Losartan; D019331:NG-Nitroarginine Methyl Ester; D007213:Indomethacin